NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events
Research Theme

Cancer

You are here: Home > Research Overview > Cancer

Cancer

The priorities for this theme are diagnosing cancer early and preventing existing cancers from progressing. We aim to achieve this by identifying those patients at highest risk.

Half of the UK population will be diagnosed with cancer during their lifetime and cancer care costs the NHS more than £10bn a year. If the disease is diagnosed early, it means effective treatments, such as surgery, can be carried out, resulting in better outcomes for patients and reduced treatment costs.

Immunotherapies are an effective treatment that harness the patient’s immune system to control the growth of cancers. However, currently 45 percent of cancers are diagnosed at late-stage and immunotherapies are mainly applied to late-stage cancers. We want to assess how effective immunotherapies are if we detect cancers at an early stage – or predict those people most likely to develop them.

There are a number of conditions that predispose individuals to getting cancer. We are focusing on three: Barrett’s oesophagus, which has a five percent chance of leading to oesophageal cancer; primary sclerosing cholangitis, which can lead to liver cancer; and some precursors to blood cancers, such as MGUS (Monoclonal gammopathy of undetermined significance) and MBL (Monoclonal B lymphocytosis).

Currently, we cannot tell which people with these conditions will go on to develop cancer. We must simply monitor them regularly and then act if they do get cancer. We want to be able to identify the people most at risk of going on to develop cancer, and we are doing that by looking for the biomarkers – molecular changes identified by imaging or in blood or tissue biopsies – that indicate a patient is transiting to cancer, enabling us to act at the very earliest signs of cancer.

This entails observing what changes take place as the pre-cancerous condition progresses to cancer through biopsies and blood samples. We assess how the cells are communicating with each other, particularly how the immune system is communicating with other tissue and how that relationship changes as we go from, for example, Barrett’s oesophagus to cancer. We believe the immune system is key to understanding what is happening in that tissue. [sub themes 2 & 3 )

As well as those who do not yet have cancer but who are at high risk of developing it, we are focusing on those who have operable early cancer and are at high risk of metastasis, when the cancer spreads to other parts of the body.

We are also looking for new biomarkers. We want to identify new targets that we can implement at an early stage, before the cancer arises or at the very earliest signs of cancer. This includes looking for better antigens – which can prompt an immune response – that might be used in the future for vaccination.

We are working closely with colleagues in other BRC themes, such as Inflammation across Tissues, Imaging, Surgical Innovation Technology and Evaluation, Metabolic Experimental Medicine, Gene and Cell Therapy and Life Saving Vaccines.

We have four sub-themes

  • Sub-theme 1: Targeted surveillance in high-risk cohorts for early cancer diagnosis

Led by Professor James East

  • Sub-theme 2: Tissue-tumour microenvironment

Led by Professor Tim Elliott

  • Sub-theme 3: Clinical markers of inflammation and immune dysregulation

Led by Professor Anna Schuh and Professor Tim Elliott

  • Sub-theme 4: Early intervention

Led by Professor Mark Middleton and Professor Anna Schuh)

We anticipate that the findings of our research will be the basis for new clinical pathways for millions of people currently attending NHS surveillance clinics. By understanding the risk better, we will reduce anxiety for people at low risk of developing cancer and improve the care and treatment of those at high risk by being able to intervene earlier. This will also reduce the NHS burden of following up people for pre-cancerous conditions and treating patients presenting with late-stage cancer.

Learn more about our work in early liver cancer detection.

Cancer

Cancer icon
  • Cancer
  • Contacts
  • Videos
  • News

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre